prednisone has been researched along with Alopecia in 91 studies
Prednisone: A synthetic anti-inflammatory glucocorticoid derived from CORTISONE. It is biologically inert and converted to PREDNISOLONE in the liver.
prednisone : A synthetic glucocorticoid drug that is particularly effective as an immunosuppressant, and affects virtually all of the immune system. Prednisone is a prodrug that is converted by the liver into prednisolone (a beta-hydroxy group instead of the oxo group at position 11), which is the active drug and also a steroid.
Alopecia: Absence of hair from areas where it is normally present.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Chlorambucil may hold advantages over the immunosuppressive drugs normally recommended in this condition, azathioprine and cyclophosphamide, as it appears less liable to cause important marrow suppression and, unlike cyclophosphamide is not associated with alopecia and haemorrhagic cystitis." | 7.65 | Treatment of patients with systemic lupus erythematosus including nephritis with chlorambucil. ( Dunnill, MS; Halley, W; Holt, JM; Oliver, DO; Snaith, ML; Stephenson, AC, 1973) |
| "To evaluate the efficacy and safety of methotrexate (MTX) used alone or combined with low- to moderate-dose oral corticosteroids (OC) for treating severe AA (totalis, universalis and severe multifocal)." | 5.43 | Efficacy and Safety of Methotrexate Combined with Low- to Moderate-Dose Corticosteroids for Severe Alopecia Areata. ( Anuset, D; Bernard, P; Perceau, G; Reguiai, Z, 2016) |
| "Oral prednisone was given at an initial dosage of 10 mg/d in one patient and 20 mg/d in 15 patients." | 5.33 | The use of methotrexate alone or in combination with low doses of oral corticosteroids in the treatment of alopecia totalis or universalis. ( Joly, P, 2006) |
| "Seventy-five female patients suffering from advanced breast cancer were treated with toilet mastectomy, radiotherapy and oophorectomy (if premenopausal) or tamoxifen therapy (if postmenopausal) as well as chemotherapy with cyclophosphamide, methotrexate, 5-fluorouracil and prednisone." | 3.68 | Toxicity and side-effects of combination chemohormonal therapy of advanced breast cancer. ( Dandapat, MC; Mohapatro, SK; Padhi, NC, 1992) |
| "Forty-seven adults with advanced malignant lymphoma (the majority in stage IV) were treated with a combination of cyclophosphamide, hydroxyldaunorubicin (Adriamycin), vincristine (Oncovin), prednisone, and bleomycin (CHOP-Bleo)." | 3.65 | Combination chemotherapy ("CHOP-Bleo") in advanced (non-Hodgkin) malignant lymphoma. ( Bodey, GP; Burgess, MA; Cabanillas, F; Freireich, EJ; McKelvey, EM; Rodriguez, V; Valdivieso, M, 1977) |
| " Chlorambucil may hold advantages over the immunosuppressive drugs normally recommended in this condition, azathioprine and cyclophosphamide, as it appears less liable to cause important marrow suppression and, unlike cyclophosphamide is not associated with alopecia and haemorrhagic cystitis." | 3.65 | Treatment of patients with systemic lupus erythematosus including nephritis with chlorambucil. ( Dunnill, MS; Halley, W; Holt, JM; Oliver, DO; Snaith, ML; Stephenson, AC, 1973) |
| "Twenty-five patients with advanced metastatic breast cancer were treated with the combination of methotrexate 60 mg/M(2) and 5-fluorouracil 700 mg/M(2) intravenously on the first and eighth days, and cyclophosphamide 100 mg/M(2) and prednisone 40 mg/M(2) by mouth daily for the first 14 days of a 28-day cycle." | 3.65 | Cyclical combination chemotherapy for advanced breast carcinoma. ( Canellos, GP; Chabner, BA; Devita, VT; Gold, GL; Schein, PS; Young, RC, 1974) |
| " Prednisolone dosage was gradually tapered to 10 mg/d at 6 months, when cyclophosphamide was replaced by azathioprine (2 mg/kg/d p." | 2.69 | Treatment of membranous lupus nephritis with nephrotic syndrome by sequential immunosuppression. ( Chan, KW; Chan, TM; Hao, WK; Lai, KN; Li, FK; Lui, SL; Tang, S, 1999) |
| "Leukopenia was the dose-limiting toxicity with all three regimens." | 2.64 | Combination chemotherapy and adriamycin in patients with advanced breast cancer. A Southwest Oncology Group study. ( Bonnet, JD; Braine, H; Costanzi, JJ; George, SL; Hoogstraten, B; Rivkin, SE; Samal, B; Thigpen, T, 1976) |
| "To date, all available therapies for prostate cancer are plagued by adverse effects." | 2.41 | Complications of chemotherapy for prostate cancer. ( Beer, TM; Bubalo, JS, 2001) |
| "To evaluate the efficacy and safety of methotrexate (MTX) used alone or combined with low- to moderate-dose oral corticosteroids (OC) for treating severe AA (totalis, universalis and severe multifocal)." | 1.43 | Efficacy and Safety of Methotrexate Combined with Low- to Moderate-Dose Corticosteroids for Severe Alopecia Areata. ( Anuset, D; Bernard, P; Perceau, G; Reguiai, Z, 2016) |
| "Satoyoshi syndrome is a rare multisystemic disease of presumed autoimmune etiology characterized by progressive painful intermittent muscle spasms, diarrhea frequently associated with malabsorption, alopecia, skeletal abnormalities and endocrine disorders with a poor long-term prognosis due to early crippling." | 1.35 | [Satoyoshi syndrome: report of one case]. ( Castiglioni, C; Díaz, A; Hernández, C; Mericq, V; Moënne, K; Salvador, F, 2009) |
| "Oral prednisone was given at an initial dosage of 10 mg/d in one patient and 20 mg/d in 15 patients." | 1.33 | The use of methotrexate alone or in combination with low doses of oral corticosteroids in the treatment of alopecia totalis or universalis. ( Joly, P, 2006) |
| "The VKH syndrome has been reported to occur in association with other autoimmune disorders." | 1.32 | Vogt-Koyanagi-Harada syndrome and ulcerative colitis. ( Federman, DG; Judson, PH; Kirsner, RS; Kravetz, JD; Ruser, CB, 2004) |
| "Satoyoshi syndrome is a rare disorder of unknown etiology characterized by progressive, painful intermittent muscle spasms, severe skeletal abnormalities mimicking a skeletal dysplasia, malabsorption, alopecia, and amenorrhea." | 1.30 | Radiological and orthopedic abnormalities in Satoyoshi syndrome. ( Ehlayel, MS; Haymon, M; Lacassie, Y; Willis, RB, 1997) |
| "infusions in the treatment of B cell chronic lymphocytic leukemia (B-CLL) in patients 55 years old and younger." | 1.30 | 2-Chlorodeoxyadenosine (Cladribine) in the treatment of patients with chronic lymphocytic leukemia 55 years old and younger. ( Błasińska-Morawiec, M; Błoński, JZ; Robak, T; Skotnicki, AB; Urbańska-Ryś, H, 1999) |
| "Thirty-eight patients with advanced Hodgkin's disease were treated with a combination of cyclophosphamide, vinblastine, procarbazine, and prednisone (CVPP)." | 1.26 | Combinaed chemotherapy with cyclophosphamide, vinblastine, procarbazine, and prednisone (CVPP) for patients with advanced Hodgkin's disease. An alternative program to MOPP. ( Bloomfield, CD; Fortuny, I; Kennedy, BJ; Vosika, G; Weiss, RB, 1976) |
| "Seventy-two women with metastatic breast cancer were treated with multiple-agent chemotherapy." | 1.26 | Combination chemotherapy in the treatment of advanced breast cancer. ( Dao, TL; Nemoto, T; Rosner, D, 1976) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 52 (57.14) | 18.7374 |
| 1990's | 11 (12.09) | 18.2507 |
| 2000's | 16 (17.58) | 29.6817 |
| 2010's | 9 (9.89) | 24.3611 |
| 2020's | 3 (3.30) | 2.80 |
| Authors | Studies |
|---|---|
| Zhou, X | 1 |
| Wang, Y | 1 |
| Li, X | 1 |
| Zhuo, XW | 1 |
| Fang, F | 1 |
| Gong, S | 1 |
| Feng, WX | 1 |
| Ding, CH | 1 |
| Xiang, X | 1 |
| Ge, M | 1 |
| Zhang, N | 1 |
| Li, JW | 1 |
| Marsh, RL | 1 |
| Spohn, GP | 1 |
| Kaffenberger, JA | 1 |
| Avilés, A | 1 |
| Nambo, MJ | 1 |
| Neri, N | 1 |
| Watanabe-Okada, E | 1 |
| Inazumi, T | 1 |
| Matsukawa, H | 1 |
| Ohyama, M | 1 |
| Flinn, IW | 1 |
| van der Jagt, R | 1 |
| Kahl, BS | 1 |
| Wood, P | 1 |
| Hawkins, TE | 1 |
| Macdonald, D | 1 |
| Hertzberg, M | 1 |
| Kwan, YL | 1 |
| Simpson, D | 1 |
| Craig, M | 1 |
| Kolibaba, K | 1 |
| Issa, S | 1 |
| Clementi, R | 1 |
| Hallman, DM | 1 |
| Munteanu, M | 1 |
| Chen, L | 1 |
| Burke, JM | 1 |
| Manríquez, J | 1 |
| Niklitschek, S | 1 |
| Anuset, D | 1 |
| Perceau, G | 1 |
| Bernard, P | 1 |
| Reguiai, Z | 1 |
| Niu, Y | 1 |
| Shi, YK | 1 |
| He, XH | 1 |
| Feng, FY | 1 |
| Zhou, LQ | 1 |
| Gu, DZ | 1 |
| Castiglioni, C | 1 |
| Díaz, A | 1 |
| Moënne, K | 1 |
| Mericq, V | 1 |
| Salvador, F | 1 |
| Hernández, C | 1 |
| El Halim Mohamed Abu Hamar, A | 1 |
| Mansour, S | 1 |
| El Shebiney, M | 1 |
| El Bary, NM | 1 |
| Sadaka, E | 1 |
| Maria, A | 1 |
| Zegarska, B | 1 |
| Kallas, D | 1 |
| Schwartz, RA | 1 |
| Czajkowski, R | 1 |
| Uchanska, G | 1 |
| Placek, W | 1 |
| Fernández-Morano, T | 1 |
| Aguilar-Bernier, M | 1 |
| Del Boz, J | 1 |
| Fúnez-Liébana, R | 1 |
| Goñi Esarte, S | 1 |
| Arín Letamendía, A | 1 |
| Vila Costas, JJ | 1 |
| Jiménez Pérez, FJ | 1 |
| Ruiz-Clavijo García, D | 1 |
| Carrascosa Gil, J | 1 |
| Almendral López, ML | 1 |
| Sato-Kawamura, M | 1 |
| Aiba, S | 1 |
| Tagami, H | 1 |
| Douri, T | 1 |
| Chawaf, AZ | 1 |
| Alrefaee, BA | 1 |
| SCHROPL, E | 1 |
| SCHROPL, V | 1 |
| FUNK, CF | 1 |
| ALVERDES, L | 1 |
| SCHMIDT, G | 1 |
| HARNACK, K | 1 |
| EL-NASR, HS | 1 |
| EL-HEFNAWI, H | 1 |
| DEWAR, HA | 1 |
| PEASTON, MJ | 1 |
| KOUBA, K | 1 |
| STAFOVA, J | 1 |
| RUSSELL, B | 1 |
| Imai, Y | 1 |
| Isoda, K | 1 |
| Ito, E | 1 |
| Hakamada, A | 1 |
| Yamanishi, K | 1 |
| Mizutani, H | 1 |
| Kamat, D | 1 |
| Petry, L | 1 |
| Berry, S | 1 |
| Federman, DG | 1 |
| Kravetz, JD | 1 |
| Ruser, CB | 1 |
| Judson, PH | 1 |
| Kirsner, RS | 1 |
| Pournaras, CC | 1 |
| Masouye, I | 1 |
| Piletta, P | 1 |
| Piguet, V | 2 |
| Saurat, JH | 2 |
| French, LE | 1 |
| Joly, P | 1 |
| Sampson, JE | 1 |
| Harmon, ML | 1 |
| Cushman, M | 1 |
| Krawitt, EL | 1 |
| Huang, HQ | 1 |
| Lin, XB | 1 |
| Pan, ZH | 1 |
| Bu, Q | 1 |
| Gao, Y | 1 |
| Wang, BF | 1 |
| Cai, QQ | 1 |
| Xia, ZJ | 1 |
| Xu, RH | 1 |
| Jiang, WQ | 1 |
| Guan, ZZ | 1 |
| Bartels, H | 1 |
| Schneider, B | 1 |
| Feller, AC | 1 |
| Pinnamaneni, K | 1 |
| Yap, HY | 1 |
| Buzdar, AU | 1 |
| Distefano, A | 1 |
| Blumenschein, GR | 1 |
| Bogusławska-Jaworska, J | 1 |
| Kościelniak, E | 1 |
| Sroczyńska, M | 1 |
| Sońta-Jakimczyk, D | 1 |
| Armata, J | 1 |
| Balwierz, W | 1 |
| Ciepielewska, D | 1 |
| Kaczmarek-Kanold, M | 1 |
| Ochocka, M | 1 |
| Radwańska, U | 1 |
| Waibel, PJ | 1 |
| Jungi, WF | 1 |
| Senn, HJ | 1 |
| Hirshaut, Y | 1 |
| Kesselheim, H | 1 |
| Vaughn, CB | 1 |
| Maniscalco-Greb, E | 1 |
| Lockhard, C | 1 |
| Groshko, G | 1 |
| Enochs, K | 1 |
| Duffin, H | 1 |
| Demitrish, M | 1 |
| Nashel, DJ | 1 |
| Ulmer, CC | 1 |
| Cunningham, ET | 1 |
| Demetrius, R | 1 |
| Frieden, IJ | 1 |
| Emery, HM | 1 |
| Irvine, AR | 1 |
| Good, WV | 1 |
| Holm, AL | 1 |
| Bowers, KE | 1 |
| McMeekin, TO | 1 |
| Gaspari, AA | 1 |
| Kossard, S | 1 |
| Lee, MS | 1 |
| Wilkinson, B | 1 |
| Haymon, M | 1 |
| Willis, RB | 1 |
| Ehlayel, MS | 1 |
| Lacassie, Y | 1 |
| Berger, JR | 1 |
| Gallo, B | 1 |
| Allbritton, J | 1 |
| Simmons-O'Brien, E | 1 |
| Hutcheons, D | 1 |
| Whitmore, SE | 1 |
| Fierro, MT | 1 |
| Quaglino, P | 1 |
| Savoia, P | 1 |
| Verrone, A | 1 |
| Bernengo, MG | 1 |
| Robak, T | 1 |
| Błoński, JZ | 1 |
| Urbańska-Ryś, H | 1 |
| Błasińska-Morawiec, M | 1 |
| Skotnicki, AB | 1 |
| Chan, TM | 1 |
| Li, FK | 1 |
| Hao, WK | 1 |
| Chan, KW | 1 |
| Lui, SL | 1 |
| Tang, S | 1 |
| Lai, KN | 1 |
| Lishner, M | 1 |
| Manor, Y | 1 |
| Kitay-Cohen, Y | 1 |
| Avishay, AE | 1 |
| Beer, TM | 1 |
| Bubalo, JS | 1 |
| Leblond, V | 1 |
| Lévy, V | 1 |
| Maloisel, F | 1 |
| Cazin, B | 1 |
| Fermand, JP | 1 |
| Harousseau, JL | 1 |
| Remenieras, L | 1 |
| Porcher, R | 1 |
| Gardembas, M | 1 |
| Marit, G | 1 |
| Deconinck, E | 1 |
| Desablens, B | 1 |
| Guilhot, F | 1 |
| Philippe, G | 1 |
| Stamatoullas, A | 1 |
| Guibon, O | 1 |
| Friedli, A | 1 |
| Pessina, PA | 1 |
| Chavaz, P | 1 |
| Economopoulos, T | 1 |
| Dimopoulos, MA | 1 |
| Mellou, S | 1 |
| Pavlidis, N | 1 |
| Samantas, E | 1 |
| Nicolaides, C | 1 |
| Tsatalas, C | 1 |
| Papadopoulos, A | 1 |
| Papageogriou, E | 1 |
| Papasavvas, P | 1 |
| Fountzilas, G | 1 |
| Hidalgo-Tenorio, C | 1 |
| Sabio, JM | 1 |
| Jiménez-Alonso, J | 1 |
| Rodriguez, V | 1 |
| Cabanillas, F | 1 |
| Burgess, MA | 1 |
| McKelvey, EM | 1 |
| Valdivieso, M | 1 |
| Bodey, GP | 1 |
| Freireich, EJ | 1 |
| Hohmeister, R | 1 |
| Waldburger, M | 1 |
| Hughes, GR | 1 |
| Unger, WP | 3 |
| Schemmer, RJ | 1 |
| Hoogstraten, B | 1 |
| George, SL | 1 |
| Samal, B | 1 |
| Rivkin, SE | 1 |
| Costanzi, JJ | 1 |
| Bonnet, JD | 1 |
| Thigpen, T | 1 |
| Braine, H | 1 |
| Bloomfield, CD | 1 |
| Weiss, RB | 1 |
| Fortuny, I | 1 |
| Vosika, G | 1 |
| Kennedy, BJ | 1 |
| Rosner, D | 1 |
| Nemoto, T | 1 |
| Dao, TL | 1 |
| von Lieven, H | 1 |
| Heinze, HG | 1 |
| Lampert, F | 1 |
| Smyth, CJ | 1 |
| Bartholomew, BA | 1 |
| Mills, DM | 1 |
| Steigerwald, JC | 1 |
| Strong, SJ | 1 |
| Recart, S | 1 |
| Mohapatro, SK | 1 |
| Dandapat, MC | 1 |
| Padhi, NC | 1 |
| Rothfield, NF | 1 |
| White, WB | 1 |
| Shornick, JK | 1 |
| Grant-Kels, JM | 1 |
| Ballow, M | 1 |
| Leonard, RC | 2 |
| Lucraft, HH | 2 |
| Proctor, SJ | 1 |
| Allan, NC | 1 |
| Dawson, AA | 1 |
| McGillivray, JB | 1 |
| Parker, AC | 1 |
| Prescott, RJ | 1 |
| van Joost, T | 1 |
| Stolz, E | 1 |
| Habets, W | 1 |
| Notowicz, A | 1 |
| Carter, SK | 1 |
| McDonald, J | 1 |
| Murphy, AV | 1 |
| Arneil, GC | 1 |
| Pambor, M | 1 |
| Rosner, J | 1 |
| Kisielewska, W | 1 |
| Koranda, FC | 1 |
| Dehmel, EM | 1 |
| Kahn, G | 1 |
| Penn, I | 1 |
| Fairley, GH | 1 |
| Freeman, JE | 1 |
| Krain, LS | 1 |
| Landau, JW | 1 |
| Newcomer, VD | 1 |
| Chiu, J | 1 |
| McLaine, PN | 1 |
| Drummond, KN | 2 |
| Snaith, ML | 1 |
| Holt, JM | 1 |
| Oliver, DO | 1 |
| Dunnill, MS | 1 |
| Halley, W | 1 |
| Stephenson, AC | 1 |
| Ahmann, DL | 1 |
| Bisel, HF | 1 |
| Hahn, RG | 1 |
| Smith, KL | 1 |
| Johnson, D | 1 |
| Hustu, O | 1 |
| Pratt, C | 1 |
| Fleming, I | 1 |
| Holton, C | 1 |
| Canellos, GP | 1 |
| Devita, VT | 1 |
| Gold, GL | 1 |
| Chabner, BA | 1 |
| Schein, PS | 1 |
| Young, RC | 1 |
| Cassady, JR | 1 |
| Jaffe, N | 1 |
| Piro, AJ | 1 |
| Wilson, RE | 1 |
| Hall, TC | 1 |
| Aliapoulios, MA | 1 |
| Nevinny, HB | 1 |
| Moore, FD | 1 |
| Bairstow, B | 1 |
| Hardisty, RM | 1 |
| McElwain, TJ | 1 |
| Darby, CW | 1 |
| Vamberová, M | 1 |
| Dietz, O | 1 |
| Hillman, DA | 1 |
| Marchessault, JH | 1 |
| Feldman, W | 1 |
| Kononenko, OG | 1 |
| Iudkina, LN | 1 |
| Fernbach, DJ | 1 |
| Griffith, KM | 1 |
| Haggard, ME | 1 |
| Holcomb, TM | 1 |
| Sutow, WW | 1 |
| Vietti, TJ | 1 |
| Windmiller, J | 1 |
| Kostanecki, W | 1 |
| Kwiatkowska, E | 1 |
| Zborzil, J | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| An Open-Label, Randomized, Parallel-Group Study of Bendamustine Hydrochloride and Rituximab (BR) Compared With Rituximab, Cyclophosphamide, Vincristine, and Prednisone (R-CVP) or Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHO[NCT00877006] | Phase 3 | 447 participants (Actual) | Interventional | 2009-04-30 | Completed | ||
| Isatuximab and Bendamustine in Systemic Light Chain Amyloidosis[NCT04943302] | Phase 2 | 0 participants (Actual) | Interventional | 2022-09-30 | Withdrawn (stopped due to PI left institution. Study not moving forward in her absence.) | ||
| A Randomized Phase II Trial Comparing BeEAM With BEAM as Conditioning Regimen for Autologous Stem Cell Transplantation (ASCT) in Lymphoma Patients (BEB-trial)[NCT02278796] | Phase 2 | 108 participants (Actual) | Interventional | 2015-04-30 | Completed | ||
| A Prospective, Open, Randomized Controlled, Multi-center Phase III Clinical Trial Comparing High-dose Epirubicin and Standard-dose Epirubicin in R±CEOP in Newly Diagnosed Young Patients With Medium/High-risk Diffuse Large B-cell Lymphoma[NCT03151044] | Phase 3 | 408 participants (Anticipated) | Interventional | 2016-07-31 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
EORTC QLQ-C30 is a 30-item questionnaire to assess the overall quality of life in cancer patients. EORTC QLQ-C30 includes functional scales (physical, role, cognitive, emotional, and social), global health status, symptom scales (fatigue, pain, nausea/vomiting), and other (dyspnoea, appetite loss, insomnia, constipation/diarrhea, and financial difficulties). This outcome reports the global health status on a scale of 0-100 with a high score for the global health status/QOL represents a high quality of life. (NCT00877006)
Timeframe: Day 1 (prior to treatment), 32 weeks
| Intervention | units on a scale (Mean) |
|---|---|
| Bendamustine and Rituximab (BR) | 3.6 |
| R-CHOP/R-CVP | -5.1 |
DOR was defined as the time from first response (CR or PR) to disease progression or relapse, or death due to any cause. (NCT00877006)
Timeframe: Day 1 up to 5.6 years (Treatment Period + Long-Term Follow-up Period)
| Intervention | months (Median) |
|---|---|
| Bendamustine and Rituximab (BR) | 26.5 |
| R-CHOP/R-CVP | 32.1 |
"EFS was defined as the time from randomization to treatment failure, disease progression or relapse, other malignancies, or death from any cause, whichever occurred first.~Treatment failure was defined as failure to achieve a CR or PR after 6 cycles of treatment. If a patient failed to achieve CR or PR by the time of data analysis or early withdrawal, the treatment failure date was set at 126 days (6 cycles of treatment) after randomization or the new anticancer treatment date, whichever is earlier." (NCT00877006)
Timeframe: Day 1 up to 5.6 years (Treatment Period + Long-Term Follow-up Period)
| Intervention | months (Median) |
|---|---|
| Bendamustine and Rituximab (BR) | 31.8 |
| R-CHOP/R-CVP | 32.6 |
PFS was defined as the time from randomization to disease progression or relapse, or death from any cause, whichever occurred first. (NCT00877006)
Timeframe: Day 1 up to 5.6 years (Treatment Period + Long-Term Follow-up Period)
| Intervention | months (Median) |
|---|---|
| Bendamustine and Rituximab (BR) | 31.8 |
| R-CHOP/R-CVP | 33.4 |
OS was defined as the time from randomization to death from any cause. (NCT00877006)
Timeframe: Day 1 up to 5.6 years (Treatment Period + Long-Term Follow-up Period)
| Intervention | months (Median) |
|---|---|
| Bendamustine and Rituximab (BR) | 65.0 |
| R-CHOP/R-CVP | 64.1 |
"Relapsed disease (after CR) and progressive disease (PD) (after PR or SD):~Lymph nodes were considered abnormal if the long axis was greater than 1.5 cm. Lymph nodes with a long axis of 1.1 to 1.5 cm were considered abnormal if its short axis was greater than 1.0 cm.~In patients with no prior history of pulmonary lymphoma, new lung nodules identified by CT require histologic confirmation.~>= 50% increase from nadir in sum of the products of the greatest diameters (SPD) of any previously involved nodes, or in a single involved node, or the size of other lesions (eg, splenic or hepatic nodules). To be considered progressive disease, a lymph node with a diameter of the short axis of less than 1.0 cm must have increased by 2: 50% and to a size of 1.5 cm by 1.5 cm, or more than 1.5 cm in the long axis~other conditions as specified in the protocol" (NCT00877006)
Timeframe: Treatment Period: 18-32 weeks Long-Term Follow-up Period: up to 5 years after the Treatment Period
| Intervention | Participants (Count of Participants) |
|---|---|
| Bendamustine and Rituximab (BR) | 36 |
| R-CHOP/R-CVP | 30 |
CR=complete disappearance of all detectable clinical evidence of disease and disease-related symptoms, if present pretherapy; protocol-specified positron emission tomography (PET) scan assessment criteria; (if the spleen and/or liver were enlarged on the basis of physical examination and/or anatomic imaging before treatment) the liver and/or spleen were considered normal size on physical examination and by anatomic imaging after therapy, with disappearance of all nodules related to lymphoma; (if the bone marrow was involved by lymphoma before treatment) the infiltrate must have cleared on subsequent bone marrow biopsies. (NCT00877006)
Timeframe: 6 to 8 21 or 28-day cycles (18-32 weeks)
| Intervention | percentage of participants (Number) |
|---|---|
| Bendamustine and Rituximab (BR) | 31 |
| R-CHOP/R-CVP | 25 |
Overall Response=participants with Complete Remission (CR) + those with Partial Remission (PR). CR=see Outcome Measure 1 for details. PR= at least a 50% decrease in the sum of the product of the greatest diameters (SPD) of up to 6 of the largest dominant nodes/masses; at least a 50% decrease in the SPD of hepatic and splenic nodules in their greatest transverse diameter; no increase in the size of the liver, spleen, and other nodes; no measurable disease in organs other than the liver or spleen; no new sites of disease; protocol-specified PET scan and bone marrow criteria. (NCT00877006)
Timeframe: 6 to 8 21 or 28-day cycles (18-32 weeks)
| Intervention | percentage of participants (Number) |
|---|---|
| Bendamustine and Rituximab (BR) | 97 |
| R-CHOP/R-CVP | 91 |
(NCT00877006)
Timeframe: 32 weeks (conducted at screening, Day 1 of each cycle, and end-of-treatment visit)
| Intervention | participants (Number) | |||||
|---|---|---|---|---|---|---|
| Heart Rate >=120 and ↑ >=15 bpm | Heart Rate <=50 and ↓ >=15 bpm | Systolic Blood Pressure(BP) >=180 and ↑ >=20 mm Hg | Systolic BP <=90 and ↓ >=20 mm Hg | Diastolic BP >=105 and ↑ from Baseline >=15 mm Hg | Diastolic BP <=50 and ↓ from Baseline >=15 mm Hg | |
| Bendamustine and Rituximab (BR) | 0 | 2 | 2 | 6 | 1 | 2 |
| R-CHOP/R-CVP | 1 | 2 | 2 | 2 | 2 | 2 |
Participants' ECOG Performance Status was evaluated at the end of treatment as improved, stayed the same, or worsened from baseline (see Baseline Characteristics for ECOG Performance Status). (NCT00877006)
Timeframe: Week 32
| Intervention | participants (Number) | ||
|---|---|---|---|
| Improved | Stayed the Same | Worsened | |
| Bendamustine/Rituximab | 32 | 153 | 34 |
| R-CHOP/R-CVP | 28 | 141 | 42 |
AE=any untoward medical occurrence that develops or worsens in severity after dispensation of the study drug and does not necessarily have a causal relationship to the study drug. An AE can, therefore, be any unfavorable and unintended physical sign, symptom, or laboratory parameter that develops or worsens in severity during the course of the study, or significant worsening of the disease under study (or any concurrent disease), whether or not considered related to the study drug. AEs were graded as 1 (mild), 2 (moderate), 3 (severe), 4 (life-threatening), 5 (death). SAE=an adverse event occurring at any dose that results in: death, a life-threatening adverse event, inpatient hospitalization or prolongation of existing hospitalization, a persistent or significant disability/incapacity (a substantial disruption of one's ability to conduct normal life functions), a congenital anomaly/birth defect, or other important medical event. (NCT00877006)
Timeframe: 32 weeks
| Intervention | participants (Number) | |||||
|---|---|---|---|---|---|---|
| Any AE | Severe AEs (grades 3, 4, 5) | Treatment-related AEs | Deaths | SAEs | Withdrawn due to AEs | |
| Bendamustine and Rituximab (BR) | 221 | 130 | 209 | 12 | 60 | 10 |
| R-CHOP/R-CVP | 213 | 127 | NA | 9 | 49 | 3 |
Death is due to any cause. Data are broken out by patients who died within 30 days of the last dose of study medications, and those who died greater than 30 days of the last dose of study medications. (NCT00877006)
Timeframe: Treatment Period: 18-32 weeks Long-Term Follow-up Period: up to 5 years after the Treatment Period
| Intervention | Participants (Count of Participants) | ||
|---|---|---|---|
| All Deaths | Deaths within 30 days of study treatment | Deaths greater than 30 days of study treatment | |
| Bendamustine and Rituximab (BR) | 40 | 2 | 38 |
| R-CHOP/R-CVP | 32 | 1 | 31 |
Participants were weighed at Baseline and at Endpoint (Week 32); those participants with an increase or decrease of >=10% were considered potentially clinically significant. (NCT00877006)
Timeframe: Baseline, Week 32
| Intervention | participants (Number) | |
|---|---|---|
| Increase >=10% | Decrease >=10% | |
| Bendamustine and Rituximab (BR) | 8 | 18 |
| R-CHOP/R-CVP | 5 | 8 |
(NCT00877006)
Timeframe: 32 weeks
| Intervention | participants (Number) | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Psycholeptics | Sex Hormones and Modulators of the Genital System | Stomatological Preparations | Throat Preparations | Thyroid Therapy | Topical Preparations for Join and Muscular Pain | Unspecified Herbal | Urologicals | Vaccines | Vasoprotectives | Vitamins | |
| Bendamustine and Rituximab (BR) | 69 | 6 | 23 | 3 | 3 | 1 | 3 | 5 | 11 | 1 | 16 |
| R-CHOP/R-CVP | 74 | 4 | 29 | 2 | 1 | 2 | 5 | 4 | 11 | 8 | 21 |
(NCT00877006)
Timeframe: prior to start of treatment
| Intervention | participants (Number) | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Psycholeptics | Sex Hormones and Modulators of the Genital System | Stomatological Preparations | Throat Preparations | Thyroid Therapy | Topical Products for Join and Muscular Pain | Unspecified Herbal | Urologicals | Vaccines | Vasoprotectives | Vitamins | |
| Bendamustine and Rituximab (BR) | 57 | 11 | 0 | 0 | 16 | 1 | 10 | 20 | 2 | 0 | 70 |
| R-CHOP/R-CVP | 59 | 12 | 0 | 0 | 17 | 0 | 10 | 11 | 7 | 0 | 61 |
Clinical laboratory data were graded according to National Cancer Institute's (NCI) CTCAE version 3, and graded as 1 (mild), 2 (moderate), 3 (severe), 4 (life-threatening), 5 (death). The table presents the worst CTCAE grades for serum chemistry test results experienced by participants overall (i.e., the worst post-baseline grade value for each participant and laboratory test across all cycles). (NCT00877006)
Timeframe: 32 weeks (conducted at screening, Day 1 of each cycle, and end-of-treatment visit)
| Intervention | participants (Number) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Albumin: Grade 1 | Albumin: Grade 2 | Albumin: Grade 3 | Albumin: Grade 4 | Albumin: Grades 1-4 | Alkaline Phosphatase: Grade 1 | Alkaline Phosphatase: Grade 2 | Alkaline Phosphatase: Grade 3 | Alkaline Phosphatase: Grade 4 | Alkaline Phosphatase: Grades 1-4 | Creatinine: Grade 1 | Creatinine: Grade 2 | Creatinine: Grade 3 | Creatinine: Grade 4 | Creatinine: Grades 1-4 | Gamma-glutamyl transferase: Grade 1 | Gamma-glutamyl transferase: Grade 2 | Gamma-glutamyl transferase: Grade 3 | Gamma-glutamyl transferase: Grade 4 | Gamma-glutamyl transferase: Grades 1-4 | Hypercalcemia: Grade 1 | Hypercalcemia: Grade 2 | Hypercalcemia: Grade 3 | Hypercalcemia: Grade 4 | Hypercalcemia: Grades 1-4 | Hyperglycemia: Grade 1 | Hyperglycemia: Grade 2 | Hyperglycemia: Grade 3 | Hyperglycemia: Grade 4 | Hyperglycemia: Grades 1-4 | Hyperkalemia: Grade 1 | Hyperkalemia: Grade 2 | Hyperkalemia: Grade 3 | Hyperkalemia: Grade 4 | Hyperkalemia: Grades 1-4 | Hypernatremia: Grade 1 | Hypernatremia: Grade 2 | Hypernatremia: Grade 3 | Hypernatremia: Grade 4 | Hypernatremia: Grades 1-4 | Hypocalcemia: Grade 1 | Hypocalcemia: Grade 2 | Hypocalcemia: Grade 3 | Hypocalcemia: Grade 4 | Hypocalcemia: Grades 1-4 | Hypoglycemia: Grade 1 | Hypoglycemia: Grade 2 | Hypoglycemia: Grade 3 | Hypoglycemia: Grade 4 | Hypoglycemia: Grades 1-4 | Hypokalemia: Grade 1 | Hypokalemia: Grade 2 | Hypokalemia: Grade 3 | Hypokalemia: Grade 4 | Hypokalemia: Grades 1-4 | Hyponatremia: Grade 1 | Hyponatremia: Grade 2 | Hyponatremia: Grade 3 | Hyponatremia: Grade 4 | Hyponatremia: Grades 1-4 | Magnesium: Grade 1 | Magnesium: Grade 2 | Magnesium: Grade 3 | Magnesium: Grade 4 | Magnesium: Grades 1-4 | Phosphorus: Grade 1 | Phosphorus: Grade 2 | Phosphorus: Grade 3 | Phosphorus: Grade 4 | Phosphorus: Grades 1-4 | Aspartate Aminotransferase: Grade 1 | Aspartate Aminotransferase: Grade 2 | Aspartate Aminotransferase: Grade 3 | Aspartate Aminotransferase: Grade 4 | Aspartate Aminotransferase: Grades 1-4 | Alanine Aminotransferase: Grade 1 | Alanine Aminotransferase: Grade 2 | Alanine Aminotransferase: Grade 3 | Alanine Aminotransferase: Grade 4 | Alanine Aminotransferase: Grades 1-4 | Total Bilirubin: Grade 1 | Total Bilirubin: Grade 2 | Total Bilirubin: Grade 3 | Total Bilirubin: Grade 4 | Total Bilirubin: Grades 1-4 | Uric Acid: Grade 1 | Uric Acid: Grade 2 | Uric Acid: Grade 3 | Uric Acid: Grade 4 | Uric Acid: Grades 1-4 | |
| Bendamustine and Rituximab (BR) | 33 | 14 | 3 | 0 | 50 | 41 | 1 | 0 | 0 | 42 | 19 | 3 | 1 | 0 | 23 | 31 | 18 | 3 | 0 | 52 | 6 | 0 | 1 | 0 | 7 | 94 | 20 | 15 | 0 | 129 | 7 | 3 | 1 | 0 | 11 | 8 | 0 | 0 | 0 | 8 | 36 | 8 | 1 | 3 | 48 | 15 | 1 | 0 | 0 | 16 | 18 | 0 | 0 | 0 | 18 | 40 | 0 | 0 | 0 | 40 | 46 | 0 | 0 | 0 | 46 | 7 | 25 | 3 | 0 | 35 | 42 | 2 | 1 | 0 | 45 | 46 | 6 | 2 | 0 | 54 | 14 | 1 | 0 | 0 | 15 | 41 | 0 | 0 | 1 | 42 |
| R-CHOP/R-CVP | 44 | 13 | 0 | 0 | 57 | 25 | 3 | 0 | 0 | 28 | 25 | 1 | 0 | 0 | 26 | 37 | 10 | 6 | 0 | 53 | 6 | 0 | 0 | 0 | 6 | 74 | 34 | 15 | 1 | 124 | 8 | 1 | 0 | 0 | 9 | 10 | 0 | 0 | 0 | 10 | 28 | 6 | 0 | 0 | 34 | 10 | 0 | 0 | 0 | 10 | 16 | 0 | 1 | 0 | 17 | 28 | 0 | 5 | 0 | 33 | 44 | 1 | 1 | 0 | 46 | 5 | 22 | 3 | 1 | 31 | 32 | 2 | 1 | 0 | 35 | 38 | 3 | 1 | 0 | 42 | 7 | 0 | 0 | 0 | 7 | 42 | 0 | 0 | 0 | 42 |
Hematology test data were graded according to National Cancer Institute's (NCI) CTCAE version 3, and graded as 1 (mild), 2 (moderate), 3 (severe), 4 (life-threatening), 5 (death). The table presents the worst CTCAE grades for hematology test results experienced by participants overall (i.e., the worst post-baseline grade value for each participant and hematology test across all cycles). (NCT00877006)
Timeframe: 32 weeks (conducted at screening, Day 1 of each cycle, weekly during treatment, and at the end-of-treatment visit)
| Intervention | participants (Number) | ||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Absolute Neutrophil Count: Grade 1 | Absolute Neutrophil Count: Grade 2 | Absolute Neutrophil Count: Grade 3 | Absolute Neutrophil Count: Grade 4 | Absolute Neutrophil Count: Grades 1-4 | Hemoglobin: Grade 1 | Hemoglobin: Grade 2 | Hemoglobin: Grade 3 | Hemoglobin: Grade 4 | Hemoglobin: Grades 1-4 | Lymphocytes Absolute: Grade 1 | Lymphocytes Absolute: Grade 2 | Lymphocytes Absolute: Grade 3 | Lymphocytes Absolute: Grade 4 | Lymphocytes Absolute: Grades 1-4 | Platelets: Grade 1 | Platelets: Grade 2 | Platelets: Grade 3 | Platelets: Grade 4 | Platelets: Grades 1-4 | White Blood Cells: Grade 1 | White Blood Cells: Grade 2 | White Blood Cells: Grade 3 | White Blood Cells: Grade 4 | White Blood Cells: Grades 1-4 | |
| Bendamustine and Rituximab (BR) | 22 | 51 | 48 | 50 | 171 | 129 | 42 | 5 | 1 | 177 | 1 | 5 | 54 | 83 | 143 | 106 | 14 | 9 | 7 | 136 | 41 | 79 | 65 | 19 | 204 |
| R-CHOP/R-CVP | 14 | 20 | 47 | 104 | 185 | 129 | 51 | 7 | 2 | 189 | 6 | 55 | 55 | 9 | 125 | 72 | 14 | 7 | 8 | 101 | 22 | 49 | 89 | 27 | 187 |
3 reviews available for prednisone and Alopecia
| Article | Year |
|---|---|
Complications of chemotherapy for prostate cancer.
Topics: Adenocarcinoma; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Docetaxel; Ga | 2001 |
[Disseminated lupus erythematosus: an analysis of organ involvement].
Topics: Abortion, Spontaneous; Adolescent; Adult; Alopecia; Antibodies, Antinuclear; Arthritis, Rheumatoid; | 1978 |
Current status of new agents.
Topics: Alopecia; Animals; Antibiotics, Antineoplastic; Antineoplastic Agents; Azacitidine; Azaguanine; Carm | 1972 |
11 trials available for prednisone and Alopecia
| Article | Year |
|---|---|
Randomized trial of bendamustine-rituximab or R-CHOP/R-CVP in first-line treatment of indolent NHL or MCL: the BRIGHT study.
Topics: Adult; Aged; Aged, 80 and over; Alopecia; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Com | 2014 |
Randomized trial of bendamustine-rituximab or R-CHOP/R-CVP in first-line treatment of indolent NHL or MCL: the BRIGHT study.
Topics: Adult; Aged; Aged, 80 and over; Alopecia; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Com | 2014 |
Randomized trial of bendamustine-rituximab or R-CHOP/R-CVP in first-line treatment of indolent NHL or MCL: the BRIGHT study.
Topics: Adult; Aged; Aged, 80 and over; Alopecia; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Com | 2014 |
Randomized trial of bendamustine-rituximab or R-CHOP/R-CVP in first-line treatment of indolent NHL or MCL: the BRIGHT study.
Topics: Adult; Aged; Aged, 80 and over; Alopecia; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Com | 2014 |
Randomized trial of bendamustine-rituximab or R-CHOP/R-CVP in first-line treatment of indolent NHL or MCL: the BRIGHT study.
Topics: Adult; Aged; Aged, 80 and over; Alopecia; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Com | 2014 |
Randomized trial of bendamustine-rituximab or R-CHOP/R-CVP in first-line treatment of indolent NHL or MCL: the BRIGHT study.
Topics: Adult; Aged; Aged, 80 and over; Alopecia; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Com | 2014 |
Randomized trial of bendamustine-rituximab or R-CHOP/R-CVP in first-line treatment of indolent NHL or MCL: the BRIGHT study.
Topics: Adult; Aged; Aged, 80 and over; Alopecia; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Com | 2014 |
Randomized trial of bendamustine-rituximab or R-CHOP/R-CVP in first-line treatment of indolent NHL or MCL: the BRIGHT study.
Topics: Adult; Aged; Aged, 80 and over; Alopecia; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Com | 2014 |
Randomized trial of bendamustine-rituximab or R-CHOP/R-CVP in first-line treatment of indolent NHL or MCL: the BRIGHT study.
Topics: Adult; Aged; Aged, 80 and over; Alopecia; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Com | 2014 |
Poor survival outcome of docetaxel every three weeks plus prednisone for treatment of patients with hormone-refractory metastatic prostate cancer.
Topics: Aged; Alopecia; Anemia; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protoc | 2010 |
Treatment of membranous lupus nephritis with nephrotic syndrome by sequential immunosuppression.
Topics: Adult; Alopecia; Anti-Inflammatory Agents; Azathioprine; Cohort Studies; Cyclophosphamide; Drug Ther | 1999 |
Multicenter, randomized comparative trial of fludarabine and the combination of cyclophosphamide-doxorubicin-prednisone in 92 patients with Waldenström macroglobulinemia in first relapse or with primary refractory disease.
Topics: Adult; Aged; Alopecia; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Proto | 2001 |
Treatment of intermediate- and high-grade non-Hodgkin's lymphoma using CEOP versus CNOP.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Alopecia; Antineoplastic Combined Chemotherapy Protocols | 2002 |
Combination chemotherapy and adriamycin in patients with advanced breast cancer. A Southwest Oncology Group study.
Topics: Alopecia; Antineoplastic Agents; Breast Neoplasms; Cyclophosphamide; Doxorubicin; Drug Evaluation; D | 1976 |
Cyclophosphamide therapy for rheumatoid arthritis.
Topics: Administration, Oral; Alopecia; Arthritis, Rheumatoid; Blood Sedimentation; Clinical Trials as Topic | 1975 |
Prospective, controlled trial of cyclophosphamide therapy in children with nephrotic syndrome. Report of the International study of Kidney Disease in Children.
Topics: Adolescent; Age Factors; Alopecia; Child; Child, Preschool; Cyclophosphamide; Cystitis; Drug Evaluat | 1974 |
A controlled prospective study of cyclophosphamide in relapsing, corticosteroid-responsive, minimal-lesion nephrotic syndrome in childhood.
Topics: Adolescent; Alopecia; Child; Cyclophosphamide; Cystitis; Drug Synergism; Female; Humans; Hypercholes | 1973 |
[A contribution of the treatment of alopecia totalis].
Topics: Adolescent; Adult; Alopecia; Child; Child, Preschool; Chloroquine; Clinical Trials as Topic; Female; | 1967 |
Chemotherapy of acute leukemia in childhood. Comparison of cyclophosphamide and mercaptopurine.
Topics: Adolescent; Alopecia; Child; Child, Preschool; Cyclophosphamide; Cystitis; Drug Synergism; Female; H | 1966 |
77 other studies available for prednisone and Alopecia
| Article | Year |
|---|---|
Analysis of the effect of R-CHOP regimen of pegylated liposomal doxorubicin on elderly patients with stage Ⅲ-Ⅳ diffuse large B-cell lymphoma.
Topics: Age Factors; Aged; Aged, 80 and over; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Card | 2021 |
[Analysis of clinical and imaging features of 6 cases of linear scleroderma en coup de sabre with central nervous system involvement in children].
Topics: Alopecia; Anticonvulsants; Brain; Calcinosis; Child; Drug Resistant Epilepsy; Encephalomalacia; Fema | 2022 |
Erosive pustular dermatosis of the scalp.
Topics: Alopecia; Anti-Inflammatory Agents; Female; Humans; Meningeal Neoplasms; Meningioma; Middle Aged; Mo | 2020 |
Primary gastric diffuse large B-cell lymphoma: The role of dose-dense chemotherapy.
Topics: Adult; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Fema | 2019 |
Histopathological insights into hair loss in Cronkhite-Canada syndrome: diffuse anagen-telogen conversion precedes clinical hair loss progression.
Topics: Alopecia; Antineoplastic Agents, Hormonal; Disease Progression; Female; Hair Follicle; Humans; Hypoa | 2014 |
[Fluctuating nodules on the scalp of a child].
Topics: Alopecia; Antifungal Agents; Child; Griseofulvin; Humans; Hyphae; Male; Microsporum; Prednisone; Sta | 2015 |
Efficacy and Safety of Methotrexate Combined with Low- to Moderate-Dose Corticosteroids for Severe Alopecia Areata.
Topics: Adolescent; Adult; Alopecia; Alopecia Areata; Anti-Inflammatory Agents; Child; Dermatologic Agents; | 2016 |
[Combined-modality therapy for 150 cases of early-stage Hodgkin's lymphoma].
Topics: Adolescent; Adult; Aged; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Child; | 2008 |
[Satoyoshi syndrome: report of one case].
Topics: Adolescent; Adrenal Cortex Hormones; Alopecia; Autoimmune Diseases; Carbamazepine; Diarrhea; Female; | 2009 |
Graham-Little syndrome.
Topics: Alopecia; Female; Glucocorticoids; Humans; Keratosis; Middle Aged; Prednisone; Scalp; Scalp Dermatos | 2010 |
Cutaneous CD8+ T-cell infiltrates associated with human immunodeficiency virus.
Topics: Adenine; Alopecia; Anti-HIV Agents; Antigens, Differentiation, T-Lymphocyte; Antiretroviral Therapy, | 2012 |
[Rituximab as rescue therapy in refractory esophageal lichen planus].
Topics: Alopecia; Androstadienes; Anti-Inflammatory Agents; Antibodies, Monoclonal, Murine-Derived; Atrophy; | 2013 |
Acute diffuse and total alopecia of the female scalp. A new subtype of diffuse alopecia areata that has a favorable prognosis.
Topics: Acute Disease; Administration, Oral; Administration, Topical; Adult; Alopecia; Alopecia Areata; Biop | 2002 |
Cicatricial alopecia due to sarcoidosis.
Topics: Administration, Oral; Adult; Alopecia; Biopsy; Cicatrix; Humans; Male; Prednisone; Sarcoidosis; Skin | 2003 |
[Hair growth in alopecia gravis totalis after prednisone ointment].
Topics: Alopecia; Alopecia Areata; Hair; Humans; Ointments; Prednisone | 1957 |
[Treatment of alopecia areata with synthetic estrogens & prednisone].
Topics: Alopecia; Alopecia Areata; Diethylstilbestrol; Estradiol Congeners; Humans; Prednisone | 1957 |
[Results of treatment of advanced cases of alopecia areata with prednis one].
Topics: Alopecia; Alopecia Areata; Humans; Prednisone | 1961 |
[Critical contribution on steroid therapy of total baldness].
Topics: Alopecia; Alopecia Areata; Humans; Prednisone | 1961 |
ALOPECIA; TREATMENT WITH A LOCAL PSORALEN AND STEROID COMBINATION.
Topics: Acetates; Adolescent; Alcohols; Alopecia; Child; Ethanol; Ficusin; Humans; Hydrocortisone; Irritants | 1963 |
THREE CASES RESEMBLING POLYARTERITIS NODOSA ARISING DURING TREATMENT WITH GUANETHIDINE.
Topics: Alopecia; Chlorothiazide; Geriatrics; Guanethidine; Hypertension; Phenobarbital; Polyarteritis Nodos | 1964 |
[RARE COMPLICATIONS OF INFECTIOUS MONONUCLEOSIS].
Topics: Alopecia; Child; Chlortetracycline; Headache; Humans; Infectious Mononucleosis; Liver; Porphyrias; P | 1964 |
ATROPHIC ALOPECIA DUE TO GRANULOMATOUS INFILTRATION OF SCALP IN SYSTEMIC SARCOIDOSIS.
Topics: Alopecia; Diagnosis; Granuloma; Humans; Pathology; Prednisone; Sarcoidosis; Scalp | 1965 |
Primary cutaneous follicle center cell lymphoma of the scalp successfully treated with anti CD20 monoclonal antibody and CHOP combination therapy with no subsequent permanent loss of hair.
Topics: Adult; Alopecia; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Comb | 2003 |
A case of Satoyoshi syndrome: a multisystem disorder.
Topics: Adolescent; Alopecia; Glucocorticoids; Humans; Immunoglobulins, Intravenous; Male; Muscle Spasticity | 2003 |
Vogt-Koyanagi-Harada syndrome and ulcerative colitis.
Topics: Adult; Alopecia; Colitis, Ulcerative; Glucocorticoids; Humans; Male; Prednisone; Uveomeningoencephal | 2004 |
Extensive annular verrucous late secondary syphilis.
Topics: Adult; Alopecia; Drug Therapy, Combination; Glucocorticoids; Humans; Male; Penicillin G Benzathine; | 2005 |
The use of methotrexate alone or in combination with low doses of oral corticosteroids in the treatment of alopecia totalis or universalis.
Topics: Administration, Oral; Adult; Aged; Alopecia; Drug Therapy, Combination; Female; Glucocorticoids; Hum | 2006 |
Corticosteroid-responsive Cronkhite-Canada syndrome complicated by thrombosis.
Topics: Alopecia; Anticoagulants; Glucocorticoids; Humans; Hyperpigmentation; Intestinal Polyposis; Intestin | 2007 |
[CEOP regimen in the treatment for non-Hodgkin's lymphoma].
Topics: Adolescent; Adult; Aged; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Child; Combined M | 2007 |
[Clinical aspects and therapy of anaplastic T-zone lymphoma].
Topics: Alopecia; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide; Doxorubicin; | 1984 |
Adriamycin, dibromodulcitol, and mitomycin combination chemotherapy for patients with metastatic breast carcinoma previously treated with cyclophosphamide, methotrexate, 5-fluorouracil, vincristine, and prednisone.
Topics: Adult; Aged; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neopla | 1984 |
Evaluation of the LSA2L2 protocol for treatment of childhood non-Hodgkin's lymphoma. A report from the Polish Children's Leukemia/Lymphoma Study Group.
Topics: Abdominal Neoplasms; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Central Nervous Syste | 1984 |
[Chemotherapy of metastasizing breast cancer. Adriamycin mono and combination therapy after LMFP pretreatment].
Topics: Alopecia; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chlorambucil; Cyclophosp | 1983 |
Prolonged remissions of metastatic breast cancer achieved with a six-drug regimen of relatively low toxicity.
Topics: Adult; Aged; Alopecia; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast | 1983 |
VP-16 and adriamycin in patients with advanced breast cancer.
Topics: Adenocarcinoma; Adult; Aged; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Breast Neopla | 1982 |
Systemic lupus erythematosus: important considerations in the adolescent.
Topics: Adolescent; Alopecia; Anxiety; Chronic Disease; Depression; Female; Humans; Hydroxychloroquine; Lupu | 1982 |
Vogt-Koyanagi-Harada syndrome in a 4-year old child.
Topics: Alopecia; Anti-Inflammatory Agents; Antineoplastic Agents, Alkylating; Blindness; Child, Preschool; | 1995 |
Chronic cutaneous lupus erythematosus treated with thalidomide.
Topics: Adult; Alopecia; Female; Humans; Lupus Erythematosus, Discoid; Prednisone; Scalp Dermatoses; Thalido | 1993 |
Postmenopausal frontal fibrosing alopecia: a frontal variant of lichen planopilaris.
Topics: Administration, Oral; Aged; Aged, 80 and over; Alopecia; Antimalarials; Biopsy; Chloroquine; Dermato | 1997 |
Radiological and orthopedic abnormalities in Satoyoshi syndrome.
Topics: Adult; Alopecia; Amenorrhea; Body Height; Bone and Bones; Bone Diseases, Developmental; Female; Frac | 1997 |
Chronic inflammatory polyradiculoneuropathy associated with alopecia universalis.
Topics: Alopecia; Anti-Inflammatory Agents; Autoimmune Diseases; Chronic Disease; Electromyography; Humans; | 1998 |
Cronkhite-Canada syndrome: report of two cases, biopsy findings in the associated alopecia, and a new treatment option.
Topics: Aged; Alopecia; Female; Glucocorticoids; Humans; Intestinal Polyps; Nail Diseases; Prednisone; Ranit | 1998 |
Systemic polychemotherapy in the treatment of primary cutaneous lymphomas: a clinical follow-up study of 81 patients treated with COP or CHOP.
Topics: Adult; Aged; Aged, 80 and over; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Bone Marro | 1998 |
2-Chlorodeoxyadenosine (Cladribine) in the treatment of patients with chronic lymphocytic leukemia 55 years old and younger.
Topics: Adult; Alopecia; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Ch | 1999 |
Association between alopecia and response to aggressive chemotherapy in patients with Hodgkin's disease.
Topics: Adult; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Dacarbazine; Doxorubicin | 1999 |
Aching alopecia.
Topics: Aged; Alopecia; Female; Giant Cell Arteritis; Glucocorticoids; Humans; Prednisone | 2002 |
Alopecia in Wegener's granulomatosis.
Topics: Alopecia; Cyclophosphamide; Female; Glucocorticoids; Granulomatosis with Polyangiitis; Humans; Immun | 2002 |
Combination chemotherapy ("CHOP-Bleo") in advanced (non-Hodgkin) malignant lymphoma.
Topics: Adult; Aged; Alopecia; Bleomycin; Bone Marrow; Cell Transformation, Neoplastic; Cyclophosphamide; Do | 1977 |
Corticosteroids in the treatment of alopecia totalis. Systemic effects.
Topics: Administration, Oral; Administration, Topical; Adolescent; Adrenal Cortex Hormones; Adult; Alopecia; | 1978 |
Combinaed chemotherapy with cyclophosphamide, vinblastine, procarbazine, and prednisone (CVPP) for patients with advanced Hodgkin's disease. An alternative program to MOPP.
Topics: Adolescent; Adult; Age Factors; Aged; Alopecia; Antineoplastic Agents; Cyclophosphamide; Drug Therap | 1976 |
Combination chemotherapy in the treatment of advanced breast cancer.
Topics: Adrenalectomy; Alopecia; Antineoplastic Agents; Breast Neoplasms; Cyclophosphamide; Drug Therapy, Co | 1976 |
["Preventive" cranial irradiation in acute lymphoblastic leukemia in childhood].
Topics: Acute Disease; Adolescent; Age Factors; Alopecia; Brain Neoplasms; Child; Child, Preschool; Cyclopho | 1976 |
Toxicity and side-effects of combination chemohormonal therapy of advanced breast cancer.
Topics: Alopecia; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Combined Modality Therap | 1992 |
The diagnostic features of SLE.
Topics: Adult; Alopecia; Blood Chemical Analysis; Exanthema; Female; Humans; Lupus Erythematosus, Systemic; | 1989 |
Erythroderma with spongiotic dermatitis. Association with common variable hypogammaglobulinemia.
Topics: Agammaglobulinemia; Aged; Alopecia; B-Lymphocytes; Dermatitis; Dermatitis, Exfoliative; Edema; Human | 1985 |
Methylprednisolone, etoposide, vindesine, and chlorambucil (PEEC) alone or alternating with CHOP as initial or salvage therapy for non-Hodgkin's lymphoma.
Topics: Adult; Aged; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Chlorambucil; Cyclophosphamid | 1988 |
[Chronic discoid lupus erythematosus; who is afraid of the red wolf?].
Topics: Adult; Alopecia; Antimalarials; Azathioprine; Facial Dermatoses; Female; Glossitis; Humans; Lupus Er | 1985 |
Long-term assessment of cyclophosphamide therapy for nephrosis in children.
Topics: Adolescent; Age Factors; Alopecia; Azathioprine; Child; Child, Preschool; Cyclophosphamide; Cystitis | 1974 |
[A clinical contribution on idiopathic follicular mucinosis (alopecia mucinosa H. Pinkus)].
Topics: Adolescent; Alopecia; Climate; Humans; Hyaluronoglucosaminidase; Male; Mucinosis, Follicular; Penici | 1967 |
[Follicular mucinosis].
Topics: Alopecia; Humans; Male; Middle Aged; Mucinosis, Follicular; Prednisone; Skin; Skin Diseases | 1968 |
Cutaneous complications in immunosuppressed renal homograft recipients.
Topics: Acne Vulgaris; Adolescent; Adult; Alopecia; Azathioprine; Carcinoma, Basal Cell; Carcinoma, Squamous | 1974 |
Letter: Treatment of alopecia totalis.
Topics: Alopecia; Humans; Prednisone | 1974 |
Blood and neoplastic diseases. Treatment of the lymphomas.
Topics: Alopecia; Bone Marrow; Cyclophosphamide; Hodgkin Disease; Humans; Lymphoma; Lymphoma, Follicular; Ne | 1974 |
Cyclophosphamide in the treatment of pemphigus vulgaris and bullous pemphigoid.
Topics: Adult; Aged; Alopecia; Cataract; Child; Cyclophosphamide; Diabetes Mellitus; Female; Humans; Leukope | 1972 |
Systemic corticosteroids in alopecia totalis.
Topics: Adolescent; Alopecia; Female; Glucocorticoids; Humans; Injections, Intradermal; Male; Middle Aged; P | 1973 |
Treatment of patients with systemic lupus erythematosus including nephritis with chlorambucil.
Topics: Adult; Alopecia; Amenorrhea; Azathioprine; Biopsy; Bone Marrow; Chlorambucil; Cyclophosphamide; Cyst | 1973 |
A phase 2 evaluation of 1-(2-chloroethyl)-3-(4- methylcyclohexyl)-1-nitrosourea (NSC 95441) in patients with advanced breast cancer.
Topics: Alopecia; Blood Platelets; Breast Neoplasms; Castration; Cyclohexanes; Cyclophosphamide; Drug Evalua | 1974 |
Concurrent chemotherapy and radiation therapy in the treatment of childhood and adolescent Hodgkin's disease.
Topics: Adolescent; Adult; Age Factors; Alopecia; Child; Child, Preschool; Cobalt Radioisotopes; Cyclophosph | 1974 |
Cyclical combination chemotherapy for advanced breast carcinoma.
Topics: Adrenalectomy; Adult; Alopecia; Bone Marrow; Bone Neoplasms; Breast Neoplasms; Castration; Cyclophos | 1974 |
Protection from chemotherapeutic epilation by prior irradiation.
Topics: Adolescent; Alopecia; Antineoplastic Agents; Child; Cyclophosphamide; Drug Therapy, Combination; Fem | 1974 |
Toxicity studies of fluorouracil used with adrenalectomy in breast cancer.
Topics: Adrenalectomy; Adult; Aged; Alopecia; Ataxia; Blood Platelet Disorders; Breast Neoplasms; Diarrhea; | 1972 |
Cicatricial pemphigoid.
Topics: Aged; Alopecia; Female; Humans; Methotrexate; Prednisone; Skin Diseases | 1971 |
Vincristine and prednisone for the induction of remissions in acute childhood leukaemia.
Topics: Acute Disease; Alopecia; Child; Child, Preschool; Drug Synergism; Gastrointestinal Diseases; Humans; | 1969 |
[Weight changes in children treated with corticoids].
Topics: Adolescent; Adrenal Cortex Hormones; Adult; Alopecia; Body Weight; Child; Dexamethasone; Female; Hum | 1967 |
Cyclophosphamide in the nephrotic syndrome of childhood: its use in two groups of patients defined by clinical, light microscopic and immunopathologic findings.
Topics: Alopecia; Biopsy; Blood Cell Count; Child; Child, Preschool; Cyclophosphamide; Female; Humans; Male; | 1968 |
[Combined treatment of patients with alopecia areata and total alopecia by using corticosteroid drugs orally and topically].
Topics: Alopecia; Alopecia Areata; Anti-Inflammatory Agents; Humans; Prednisolone; Prednisone | 1965 |
[Hair melanogenesis in endoxan alopecia and its modification by corticosteroids].
Topics: Alopecia; Breast Neoplasms; Cyclophosphamide; Female; Hair; Humans; Male; Melanins; Neoplasms; Predn | 1966 |